Historical Valuation
Halozyme Therapeutics Inc (HALO) is now in the Undervalued zone, suggesting that its current forward PE ratio of 9.25 is considered Undervalued compared with the five-year average of 14.66. The fair price of Halozyme Therapeutics Inc (HALO) is between 107.30 to 167.31 according to relative valuation methord. Compared to the current price of 73.06 USD , Halozyme Therapeutics Inc is Undervalued By 31.92%.
Relative Value
Fair Zone
107.30-167.31
Current Price：73.06
31.92%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Halozyme Therapeutics Inc (HALO) has a current Price-to-Book (P/B) ratio of 16.40. Compared to its 3-year average P/B ratio of 30.21 , the current P/B ratio is approximately -45.72% higher. Relative to its 5-year average P/B ratio of 35.36, the current P/B ratio is about -53.62% higher. Halozyme Therapeutics Inc (HALO) has a Forward Free Cash Flow (FCF) yield of approximately 7.29%. Compared to its 3-year average FCF yield of 6.39%, the current FCF yield is approximately 14.02% lower. Relative to its 5-year average FCF yield of 5.30% , the current FCF yield is about 37.35% lower.
P/B
Median3y
30.21
Median5y
35.36
FCF Yield
Median3y
6.39
Median5y
5.30
Competitors Valuation Multiple
AI Analysis for HALO
The average P/S ratio for HALO competitors is 11.27, providing a benchmark for relative valuation. Halozyme Therapeutics Inc Corp (HALO.O) exhibits a P/S ratio of 5.21, which is -53.77% above the industry average. Given its robust revenue growth of 22.12%, this premium appears sustainable.
Performance Decomposition
AI Analysis for HALO
1Y
3Y
5Y
Market capitalization of HALO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of HALO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is HALO currently overvalued or undervalued?
Halozyme Therapeutics Inc (HALO) is now in the Undervalued zone, suggesting that its current forward PE ratio of 9.25 is considered Undervalued compared with the five-year average of 14.66. The fair price of Halozyme Therapeutics Inc (HALO) is between 107.30 to 167.31 according to relative valuation methord. Compared to the current price of 73.06 USD , Halozyme Therapeutics Inc is Undervalued By 31.92% .
What is Halozyme Therapeutics Inc (HALO) fair value?
HALO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Halozyme Therapeutics Inc (HALO) is between 107.30 to 167.31 according to relative valuation methord.
How does HALO's valuation metrics compare to the industry average?
The average P/S ratio for HALO's competitors is 11.27, providing a benchmark for relative valuation. Halozyme Therapeutics Inc Corp (HALO) exhibits a P/S ratio of 5.21, which is -53.77% above the industry average. Given its robust revenue growth of 22.12%, this premium appears sustainable.
What is the current P/B ratio for Halozyme Therapeutics Inc (HALO) as of Jan 09 2026?
As of Jan 09 2026, Halozyme Therapeutics Inc (HALO) has a P/B ratio of 16.40. This indicates that the market values HALO at 16.40 times its book value.
What is the current FCF Yield for Halozyme Therapeutics Inc (HALO) as of Jan 09 2026?
As of Jan 09 2026, Halozyme Therapeutics Inc (HALO) has a FCF Yield of 7.29%. This means that for every dollar of Halozyme Therapeutics Inc’s market capitalization, the company generates 7.29 cents in free cash flow.
What is the current Forward P/E ratio for Halozyme Therapeutics Inc (HALO) as of Jan 09 2026?
As of Jan 09 2026, Halozyme Therapeutics Inc (HALO) has a Forward P/E ratio of 9.25. This means the market is willing to pay $9.25 for every dollar of Halozyme Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Halozyme Therapeutics Inc (HALO) as of Jan 09 2026?
As of Jan 09 2026, Halozyme Therapeutics Inc (HALO) has a Forward P/S ratio of 5.21. This means the market is valuing HALO at $5.21 for every dollar of expected revenue over the next 12 months.